Flint, Anne

Reproducibility, power and validity of visual analogue scales in assessment of appetite sensations in single test meal studies

Flint, A., Raben, A., Blundell, J., & Astrup, A. (2000) · International Journal of Obesity

Regulation of Appetite and ObesityNutrition, Health and Food Behavior

Cited by 2,238

Glucagon-like peptide 1 promotes satiety and suppresses energy intake in humans.

Flint, A., Raben, A., Astrup, A., & Holst, J. J. (1998) · Journal of Clinical Investigation

Regulation of Appetite and ObesityDiabetes Treatment and Management

Cited by 1,402

Effects of once‐weekly semaglutide on appetite, energy intake, control of eating, food preference and body weight in subjects with obesity

Blundell, J., Finlayson, G., Axelsen, M., Flint, A., Gibbons, C., Kvist, T., & Hjerpsted, J. B. (2017) · Diabetes, Obesity and Metabolism

Pharmacology and Obesity TreatmentRegulation of Appetite and Obesity

Cited by 693

Effects of the once-daily GLP-1 analog liraglutide on gastric emptying, glycemic parameters, appetite and energy metabolism in obese, non-diabetic adults

van Can, J., Sloth, B., Jensen, C. B., Flint, A., Blaak, E. E., & Saris, W. H. M. (2014) · International Journal of Obesity

Pharmacology and Obesity TreatmentRegulation of Appetite and Obesity

Cited by 537

The effect of physiological levels of glucagon-like peptide-1 on appetite, gastric emptying, energy and substrate metabolism in obesity

Flint, A., Raben, A., Ersbøll, A., Holst, J., & Astrup, A. (2001) · International Journal of Obesity

Regulation of Appetite and ObesityDiabetes Treatment and Management

Cited by 384

Meals with similar energy densities but rich in protein, fat, carbohydrate, or alcohol have different effects on energy expenditure and substrate metabolism but not on appetite and energy intake

Raben, A., Agerholm-Larsen, L., Flint, A., Holst, J. J., & Astrup, A. (2003) · The American Journal of Clinical Nutrition

Regulation of Appetite and ObesityNutrition, Health and Food Behavior

Cited by 365

Semaglutide improves postprandial glucose and lipid metabolism, and delays first‐hour gastric emptying in subjects with obesity

Hjerpsted, J. B., Flint, A., Brooks, A., Axelsen, M. B., Kvist, T., & Blundell, J. (2018) · Diabetes, Obesity and Metabolism

Diabetes Treatment and ManagementPharmacology and Obesity Treatment

Cited by 245

Randomised clinical trial: semaglutide versus placebo reduced liver steatosis but not liver stiffness in subjects with non‐alcoholic fatty liver disease assessed by magnetic resonance imaging

Flint, A., Andersen, G., Hockings, P., Johansson, L., Morsing, A., Sundby Palle, M., Vogl, T., Loomba, R., & Plum‐Mörschel, L. (2021) · Alimentary Pharmacology & Therapeutics

Liver Disease Diagnosis and TreatmentDiabetes Treatment and Management

Cited by 224

Liraglutide in Type 2 Diabetes Mellitus: Clinical Pharmacokinetics and Pharmacodynamics

Jacobsen, L. V., Flint, A., Olsen, A. K., & Ingwersen, S. H. (2016) · Clinical Pharmacokinetics

Diabetes Treatment and ManagementDiabetes Management and Research

Cited by 217

The use of glycaemic index tables to predict glycaemic index of composite breakfast meals

Flint, A., Møller, B. K., Raben, A., Pedersen, D., Tetens, I., Holst, J. J., & Astrup, A. (2004) · British Journal of Nutrition

Food composition and propertiesDiet, Metabolism, and Disease

Cited by 202

Associations between Postprandial Insulin and Blood Glucose Responses, Appetite Sensations and Energy Intake in Normal Weight and Overweight Individuals: A Meta-Analysis of Test Meal Studies

Flint, A., Gregersen, N. T., Gluud, L. L., Møller, B. K., Raben, A., Tetens, I., Verdich, C., & Astrup, A. (2007) · British Journal of Nutrition

Regulation of Appetite and ObesityAdipokines, Inflammation, and Metabolic Diseases

Cited by 192

Effect of the once-daily human GLP-1 analogue liraglutide on appetite, energy intake, energy expenditure and gastric emptying in type 2 diabetes

Horowitz, M., Flint, A., Jones, K. L., Hindsberger, C., Rasmussen, M. F., Kapitza, C., Doran, S., Jax, T., Zdravkovic, M., & Chapman, I. M. (2012) · Diabetes Research and Clinical Practice

Diabetes Treatment and ManagementRegulation of Appetite and Obesity

Cited by 179

Semaglutide, a once‐weekly human GLP‐1 analog, does not reduce the bioavailability of the combined oral contraceptive, ethinylestradiol/levonorgestrel

Kapitza, C., Nosek, L., Jensen, L., Hartvig, H., Jensen, C. B., & Flint, A. (2015) · The Journal of Clinical Pharmacology

Reproductive Health and ContraceptionPharmacogenetics and Drug Metabolism

Cited by 175

Dietary supplement use by varsity athletes at a Canadian university

Kristiansen, M., Levy-Milne, R., Barr, S., & Flint, A. (2005) · International Journal of Sport Nutrition and Exercise Metabolism

Doping in SportsNutrition and Health Studies

Cited by 144

Liraglutide suppresses postprandial triglyceride and apolipoprotein B48 elevations after a fat‐rich meal in patients with type 2 diabetes: a randomized, double‐blind, placebo‐controlled, cross‐over trial

Hermansen, K., Bækdal, T. A., Düring, M., Pietraszek, A., Mortensen, L. S., Jørgensen, H., & Flint, A. (2013) · Diabetes, Obesity and Metabolism

Diabetes Treatment and ManagementDiabetes, Cardiovascular Risks, and Lipoproteins

Cited by 143

Effect of subcutaneous injections of PYY1-36 and PYY3-36 on appetite, ad libitum energy intake, and plasma free fatty acid concentration in obese males

Sloth, B., Davidsen, L., Holst, J. J., Flint, A., & Astrup, A. (2007) · American Journal of Physiology-Endocrinology and Metabolism

Regulation of Appetite and ObesityNeuropeptides and Animal Physiology

Cited by 104

The once-daily human glucagon-like peptide-1 (GLP-1) analog liraglutide improves postprandial glucose levels in type 2 diabetes patients

Flint, A., Kapitza, C., Hindsberger, C., & Zdravkovic, M. (2011) · Advances in Therapy

Diabetes Treatment and ManagementDiabetes Management and Research

Cited by 91

Amycretin, a novel, unimolecular GLP-1 and amylin receptor agonist administered subcutaneously: results from a phase 1b/2a randomised controlled study

Dahl, K., Toubro, S., Dey, S., Duque do Vale, R., Flint, A., Gasiorek, A., Heydorn, A., Jastreboff, A. M., Key, C., Petersen, S. B., et al. (2025) · The Lancet

Pharmacology and Obesity TreatmentDiabetes Treatment and Management

Cited by 80

Exposure-response analysis for evaluation of semaglutide dose levels in type 2 diabetes

Petri, K. C. C., Ingwersen, S. H., Flint, A., Zacho, J., & Overgaard, R. V. (2018) · Diabetes, Obesity and Metabolism

Diabetes Treatment and ManagementDiabetes Management and Research

Cited by 53

The effect of the once-daily human glucagon-like peptide 1 analog liraglutide on the pharmacokinetics of acetaminophen

Kapitza, C., Zdravkovic, M., Hindsberger, C., & Flint, A. (2011) · Advances in Therapy

Diabetes Treatment and ManagementPharmacogenetics and Drug Metabolism

Cited by 36

A Randomized Trial Investigating the Pharmacokinetics, Pharmacodynamics, and Safety of Subcutaneous Semaglutide Once-Weekly in Healthy Male Japanese and Caucasian Subjects

Ikushima, I., Jensen, L., Flint, A., Nishida, T., Zacho, J., & Irie, S. (2018) · Advances in Therapy

Diabetes Treatment and ManagementDiabetes Management and Research

Cited by 28

No QTc Prolongation with Semaglutide: A Thorough QT Study in Healthy Subjects

Demmel, V., Sandberg-Schaal, A., Jacobsen, J. B., Golor, G., Pettersson, J., & Flint, A. (2018) · Diabetes Therapy

Cardiac electrophysiology and arrhythmiasDiabetes Treatment and Management

Cited by 16